PMC8: META-ANALYSIS OF ECONOMIC EVALUATIONS: A METHODOLOGICAL APPROACH AND CASE STUDY  by Pang, F & Drummond, M
42 Abstracts
RESULTS AND CONCLUSION: The conclusions are: (1)
it is feasible to use a surrogate sample to estimate regres-
sion models that satisfactorily relate patient utility to
readily collectible predictor variables; (2) these models can
be applied to assign plausible utility scores to subjects in a
phase III clinical trial; (3) the resulting ranking of therapies
is in accord with clinical findings from the present trial;
and (4) this strategy may be especially attractive for cost-
utility analyses that pool data from multiple trials.
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ADVANCED SENSITIVITY ANALYSIS BY THE 
INTEGRATION OF POINT-SENSITIVITY AND 
RANGE-SENSITIVITY USING PROBABILITY 
DISTRIBUTIONS
Nuijten MJC
The Lewin Group, Hoofddorp, The Netherlands
The level of uncertainty regarding the outcome of a phar-
macoeconomic study cannot be covered completely by
the statistical methods routinely employed to handle un-
certainty in clinical research. Sensitivity analysis is the
most common methodology to deal with the extra uncer-
tainty associated with pharmacoeconomics, which has
also been incorporated in recent guidelines on health care
evaluation. However, the execution of a sensitivity analy-
sis and the interpretation of the results is not yet stan-
dardized, which may lead to subjectivity and conse-
quently weakening of the value of economic evaluations. 
OBJECTIVE: The concept of point-sensitivity was used
to develop a method which allows a more objective judg-
ment of the robustness of a model by avoiding the subjec-
tiveness in most current economic studies.
RESULTS: However, a limitation of this method is that
the sensitivity measurement is based on a uniform distri-
bution of the variables, which may actually have different
distributions. A second limitation is that the overall sensi-
tivity measure is based on a subjectively chosen range, ex-
cluding the impact of values outside the range on overall
sensitivity.
CONCLUSION: The present study presents a refinement
of the method by the incorporation of probability distri-
butions, which allow a more accurate assessment of the
level of uncertainty in the model. In addition, a bootstrap
method is used to create probability distribution for fixed
input variables based on a limited number of data points.
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DIMINISHING THE COST OF HIGHLY 
PRESCRIBED DRUGS IN THE COMUNIDAD 
VALENCIANA (SPAIN)
Larruga J, Diaz R, Garcia J, Moreno R
Conselleria de Sanidad, Generalitat Valenciana, Barcelona, Spain
OBJECTIVES: Our objective is to diminish the cost of a
group of highly prescribed drugs in the Comunidad Va-
lenciana (Spain) through the promotion of prescribing
them by drug (generic) name (not registered [brand]
names), and the corresponding dispensation at phar-
macies of a selected group of registered drugs with the
same composition and size and lower price (i.e., reference
drugs). 
METHODS: The drugs representing about 50% of the
drug prescription costs for the Health Service in June
1995 were selected through analysis of pharmacy bills.
The most prescribed sizes for each drug were studied in
order to select those with minimum prices as reference
drugs. An agreement was concluded with pharmacies to
dispense these trade names when the prescription was
made by drug name. Physicians were informed in order to
promote prescription by drug name.
RESULTS: Thirty-four drugs were responsible for 45% of
the drug prescription bill of the Health Service in the
Comunidad Valenciana in June 1995. The first 10 of them
were Omeprazole, Nimodipine, Ciprofloxacin, Enalapril,
Calcitonin, Diltiazem, Fluoxetine and Nifedipine. Glob-
ally, prescriptions by drug name have increased from 0.2%
to 0.34% in 5 months. Prescription of registered names of
minimum price has increased markedly for nearly each
drug. For example, with Amoxicyllin, prescription of refer-
ence drugs in 1995 was 14.62% of the total of Amoxicyl-
lin prescriptions compared with 35.92% in 1996; for Di-
clofenac, prescriptions of reference drugs represented
15.02% of the total of Diclofenac prescriptions in 1995
compared with 31.85% in 1996. 
CONCLUSIONS: The minimum increase in dispensation of
prescription by drug names is influenced by the fact that in
Spain no generic drugs are available, and so there is a strong
tradition of prescribing by registered drug names. The agree-
ment with pharmacies represents the dispensation of a
group of selected trade names of minimum prices (reference
drugs); physicians have preferred prescribing directly the
names included in this group. The effect of diminishing
costs has been obtained with this intervention, but not by
the increase in prescriptions by drug name, as the impact
of this measure in prescribing habits has been slight.
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Meta-analysis has become an increasingly accepted re-
search tool for producing overviews of the results of clin-
ical studies. Recently, there has been a rapid increase in
the number of economic evaluations performed, and there
is both the need and the potential to produce overviews
for policy makers.
OBJECTIVE: The purpose of this research was to investi-
gate whether standard meta-analytical approaches (as ap-
plied to clinical data) could be applied to economic evalua-
tions. As a case study, an economic meta-analysis (EMA)
was conducted of cost-effectiveness analyses involving
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antithrombotic agents (standard heparin, LMW heparin,
warfarin) as prophylaxis against deep-vein thrombosis
(DVT) following total hip arthroplasty. 
METHODS: The EMA was based on an adapted Cochrane
Review framework. The objectives were (1) to determine
whether prophylaxis versus no prophylaxis is cost-effec-
tive; (2) to determine the most cost-effective agent; and
(3) to explore differences in cost-effectiveness between set-
tings. Before the literature search (databases/hand searches),
selection criteria were specified. Each eligible study was
assessed for economic and clinical quality using modified
checklists, and various clinical variables (e.g., DVT, PE
rates; mortality) and economic variables (e.g., drug acqui-
sition costs, treatment costs) were extracted and pooled.
All costs were standardized to US dollars (1997).
RESULTS: Thirty-five economic studies were retrieved,
of which 14 met the criteria for inclusion (US  5, Swe-
den  4, Canada  2, Denmark  2, UK  1). Economic
quality was generally high (71–86%), but the clinical
quality was less certain (3 “A”, 4 “B”, 7 “ungradeable”).
Although considerable variability existed across studies,
the pooled analysis showed an overall reduction in both
costs and DVT, PE and mortality rates associated with
prophylaxis versus no prophylaxis. In preventing DVT
and PE, LMW heparin was more effective than standard
heparin, but similar to warfarin. Although the acquisition
cost of LMW heparin was greater than both alternatives,
this result was offset by the reduced treatment cost for
complications. Costs tended to be higher in the US.
CONCLUSION: From this case study, we have employed
a systematic approach for reviewing economic evaluations,
and have highlighted ways the standard meta-analytical
methodology would need to be adapted to achieve reliable
and useful overviews.
